Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Which comes first: atypical antipsychotic treatment or cardiometabolic risk?

Acta psychiatrica Scandinavica - 1 Mar 2009

Stahl S M, Mignon L, Meyer J M

Abstract excerpt

OBJECTIVE: To provide an overview for practicing clinicians on the pharmacological basis of cardiometabolic risk induced by antipsychotic drugs in patients with serious mental illness, to propose hypotheses to explain these risks and to give tips for managing cardiometabolic risk during antipsychotic treatment. METHOD: A MEDLINE search using terms for atypical antipsychotics (including individual drug names),...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antipsychotic Agents
Share to Appetite
Share to Cardiovascular Diseases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cholesterol, HDL

Share to Hypertriglyceridemia

Share to Metabolic Syndrome

Share to Triglycerides

Share to Weight Gain

Source

Identifiers

PMID: 19178394
DOI: 10.1111/j.1600-0447.2008.01334.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Which comes first: atypical antipsychotic treatment or cardiometabolic risk?PMID 19178394Read ↗

Mechanisms underlying metabolic disturbances associated with psychosis and antipsychotic drug treatmentSemantic proximity Read ↗

Metabolic syndrome and insulin resistance in schizophrenia patients receiving antipsychotics genotyped for the methylenetetrahydrofolate reductase (MTHFR) 677C/T and 1298A/C variants.Semantic proximity Read ↗

[Metabolic syndrome in patients with schizophrenia independently from atypical antipsychotics intake].Semantic proximity Read ↗

Schizophrenia and cardiometabolic abnormalities: A Mendelian randomization studySemantic proximity Read ↗

HTR2C polymorphisms, olanzapine-induced weight gain and antipsychotic-induced metabolic syndrome in schizophrenia patients: a meta-analysis.Semantic proximity Read ↗

Factors in antipsychotic drug selection: tolerability considerations.Semantic proximity Read ↗

Atypical antipsychotic (AAP)-induced metabolic toxicity : study of mechanisms, biomarkers and reversal strategiesSemantic proximity Read ↗

Prevalence and factors associated of metabolic syndrome in first- treatment drug-naïve schizophrenia patients: a large-scale cross- sectional studySemantic proximity Read ↗

Gender differences in prevalence and associated factors of metabolic syndrome in first-treatment and drug-naïve schizophrenia patientsSemantic proximity Read ↗

Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle.Semantic proximity Read ↗

Genetics of antipsychotic treatment emergent weight gain in schizophrenia.Semantic proximity Read ↗

Metabolic side effects of antipsychotic drug treatment--pharmacological mechanisms.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.